Editas Medicine, Inc. — Earnings Quality Grade C
EDIT · Healthcare
Some red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 137 days, change -47 days YoY
AR growth -6.7% vs revenue growth 25.4%
Revenue 25.4%, CFFO 21.4%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -93.1% vs revenue 25.4%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.03. Profits backed by cash
FCF is negative ($-0.2B)
Accruals ratio = 2.8%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -16.1x (<2x). Financial stress
Other assets -43.0% vs revenue 25.4%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
Insufficient data
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25